Medical Condition News

RSS

MSU researchers receive $7 million NIH grant to study link between belly fat and high blood pressure

Michigan State University researchers, who were the first to suggest that high blood pressure could be caused by belly fat hormones "talking" with blood vessels in the abdomen, have received a nearly $7 million National Institutes of Health grant to further their work.

21 Apr 2015

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.

21 Apr 2015

AACR throws spotlight on the experience of Individualized Molecular Pancreatic Cancer Therapy trial

After performing thousands of unsuccessful experiments in his attempt to perfect the light bulb, Thomas Edison famously remarked: "I have not failed, not once. I've discovered ten thousand ways that don't work."

21 Apr 2015

Myc cancer gene allows tumor cells to divide, provokes cell suicide process

Myc cancer gene empowers tumor cells to relentlessly divide but simultaneously, provokes a cell suicide process called apoptosis. Myc controls cells by commanding the expression of every tenth of the genes in the nucleus of a tumor cell. However, in spite of more than two decades of intense research, no Myc motivated killer genes have been found.

21 Apr 2015

New UM SOM study reveals why thiazide drugs not effective in some patients

Every year, more than 120 million prescriptions are written worldwide for thiazide drugs, a group of salt-lowering medicines used to treat high blood pressure. These drugs are often work very well, and over decades have saved hundreds of thousands of lives.

21 Apr 2015

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

21 Apr 2015

New OCT angiography can improve clinical management of leading causes of blindness

Research published today in the Proceedings of the National Academy of Sciences demonstrates that technology invented by researchers at Oregon Health & Science University's Casey Eye Institute can improve the clinical management of the leading causes of blindness.

21 Apr 2015

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream.

20 Apr 2015

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.

20 Apr 2015

UAS therapy for OSA recognized with a Top 10 Clinical Research Achievement Award

Inspire Medical Systems, Inc., announced today that a scientific paper on its Inspire Upper Airway Stimulation (UAS) therapy for obstructive sleep apnea (OSA), has been recognized with a Top 10 Clinical Research Achievement Award from the Clinical Research Forum.

20 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc.

20 Apr 2015

Tandem Diabetes Care commences shipments of t:slim Insulin Pumps with enhanced software

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim and t:flex Insulin Pumps, today commenced shipments of t:slim Pumps featuring enhanced software.

20 Apr 2015

University of Washington receives PPMD grant to continue analysis of spectrin-like repeats in dystrophin

Parent Project Muscular Dystrophy, a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) awarded University of Washington a $148,000 grant to continue the functional analysis of spectrin-like repeats in dystrophin.

20 Apr 2015

Tackling the challenge of managing fatigue in MS patients

Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS) and can significantly reduce an individual's quality of life. Unlike the tiredness that we all experience sometimes, fatigue in those with MS can have a hugely negative impact - it can limit or stop people from doing day-to-day activities and things that really matter to them.

20 Apr 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates.

20 Apr 2015

MD Anderson researchers identify key factor that may explain drug resistance in glioblastoma

Researchers at the NFCR Center for Cancer System Informatics at MD Anderson Cancer Center have discovered a key factor that may explain drug resistance in glioblastoma (GBM), the most common and deadliest form of brain cancer.

20 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

Medical Condition News

MSU researchers receive $7 million NIH grant to study link between belly fat and high blood pressure

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

AACR throws spotlight on the experience of Individualized Molecular Pancreatic Cancer Therapy trial

Myc cancer gene allows tumor cells to divide, provokes cell suicide process

New UM SOM study reveals why thiazide drugs not effective in some patients

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New OCT angiography can improve clinical management of leading causes of blindness

MGH researchers find probable mechanism associated with risk of developing serious diseases

Two existing drugs may potentially become new drug target for multiple sclerosis

UAS therapy for OSA recognized with a Top 10 Clinical Research Achievement Award

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Lupin introduces first Brand product Zaxine in Canada

Tandem Diabetes Care commences shipments of t:slim Insulin Pumps with enhanced software

University of Washington receives PPMD grant to continue analysis of spectrin-like repeats in dystrophin

Tackling the challenge of managing fatigue in MS patients

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

MD Anderson researchers identify key factor that may explain drug resistance in glioblastoma

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News